Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Enterprise Value (2016 - 2025)

Ocular Therapeutix has reported Enterprise Value over the past 13 years, most recently at -$737.1 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$737.1 million for Q4 2025, down 87.98% from a year ago — trailing twelve months through Dec 2025 was -$737.1 million (down 87.98% YoY), and the annual figure for FY2025 was -$737.1 million, down 87.98%.
  • Enterprise Value for Q4 2025 was -$737.1 million at Ocular Therapeutix, down from -$344.8 million in the prior quarter.
  • Over the last five years, Enterprise Value for OCUL hit a ceiling of -$66.6 million in Q2 2023 and a floor of -$737.1 million in Q4 2025.
  • Median Enterprise Value over the past 5 years was -$193.9 million (2021), compared with a mean of -$264.2 million.
  • Biggest five-year swings in Enterprise Value: soared 50.49% in 2023 and later crashed 590.16% in 2024.
  • Ocular Therapeutix's Enterprise Value stood at -$164.2 million in 2021, then soared by 37.68% to -$102.3 million in 2022, then plummeted by 91.55% to -$196.0 million in 2023, then tumbled by 100.1% to -$392.1 million in 2024, then tumbled by 87.98% to -$737.1 million in 2025.
  • The last three reported values for Enterprise Value were -$737.1 million (Q4 2025), -$344.8 million (Q3 2025), and -$391.1 million (Q2 2025) per Business Quant data.